A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung(✩)

BACKGROUND: Elexacaftor-Tezacaftor-Ivacaftor (ETI) therapy is showing promising efficacy for treatment of cystic fibrosis (CF) and is becoming more widely available since recent FDA approval. However, little is known about how these drugs will affect lung infections, which are the leading cause of m...

Descripción completa

Detalles Bibliográficos
Autores principales: Sosinski, Lo M., Christian, Martin H, Neugebauer, Kerri A., Ghuneim, Lydia-Ann J., Guzior, Douglas V., Castillo-Bahena, Alicia, Mielke, Jenna, Thomas, Ryan, McClelland, Marc, Conrad, Doug, Quinn, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124239/
https://www.ncbi.nlm.nih.gov/pubmed/34824018
http://dx.doi.org/10.1016/j.jcf.2021.11.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124239/
https://www.ncbi.nlm.nih.gov/pubmed/34824018
http://dx.doi.org/10.1016/j.jcf.2021.11.003

Ejemplares similares